89bio, Inc. (ETNB)
89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.
Address
142 SANSOME STREET
SAN FRANCISCO, CA 94104
Founded
2018
Number of Employees
70
Website
http://www.89bio.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at ETNB make a trade.
Creating a free account takes less than one minute